Showing results (111-120 of 313) with videos related to

Sort By:
Pageof 32
Acta Diabetologica|May 10, 2011
Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucoseMustafa Kanat, Luke Norton, Diedre Winnier, et al.
Diabetes|April 29, 2006
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology StudyMuhammad A Abdul-Ghani, Christopher P Jenkinson, Dawn K Richardson, et al.
Metabolism: Clinical and Experimental|August 30, 2002
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individualsMasafumi Matsuda, Ralph A Defronzo, Leonard Glass, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysisAmalia Gastaldelli, Yoshinori Miyazaki, Maura Pettiti, et al.
Endocrinology|March 18, 2010
The ontogeny of insulin signaling in the preterm baboon modelCynthia L Blanco, Hanyu Liang, Joaquin Joya-Galeana, et al.
Diabetes|March 1, 2007
Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentrationMandeep Bajaj, Rafael Medina-Navarro, Swangjit Suraamornkul, et al.
Genomics Data|April 27, 2016
Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotypeChristopher P Jenkinson, Harald H H Göring, Rector Arya, et al.
Diabetes, Obesity & Metabolism|December 12, 2017
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar studyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Clinical Endocrinology|May 12, 2010
Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT studyLeonard C Glass, Kenneth Cusi, Rachele Berria, et al.
Diabetes, Obesity & Metabolism|December 22, 2023
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individualsSiham Abdelgani, Ahmed Khattab, John Adams, et al.
Pageof 32